In contrast to the findings mentioned above, a randomized controlled trial conducted in 2022 by Ikeda et al. [15] on 200 patients with HCC recorded a higher incidence of PES, including pyrexia (p=0.0001), malaise (p=0.01013), loss of appetite (p=0.0048), and elevated transaminases: aspartate transaminase (AST) and alanine transaminase (ALT) (p<0.0001), hyperbilirubinemia (p=0.0002), and hypoalbuminemia (p=0.0154) in patients who underwent cTACE than those with DEB-TACE. Here, GPT is linked to Hyperbilirubinemia.